Human Anti-MRSA Recombinant Antibody (clone MEH183) (CAT#: VS-0323-CJ35)

Figure 1 The binding specificities of MEH63, MEH158 and MEH183 were analyzed by dot blot.

The binding ability of MEH63, MEH158 and MEH183 to S. aureus S.a.124, S. epidermidis, S. pyogenes and A. baumannii A.b.56 was appraised by the dot-blot assay (Left). The cross-reactivity of scFvs with PBMCs was examined using the dot-blot assay (Right).

Figure 2 The inhibition ability of MEH63, MEH158 and MEH183 were analyzed.

MEH63, MEH158 and MEH183 (200 µg mL-1) exhibited antibacterial activity against S. aureus S.a.48, S. epidermidis and S. pyogenes, but not against A. baumannii A.b.56.

Figure 3 Target analysis by Western blot.

MEH63, MEH158 and MEH183 reacted with some cell wall proteins of S. aureus. The crude cell wall extracts (CW) of S. aureus S.a.124, as well as non-covalent bond cell wall proteins (NB) of S. aureus S.a.124, were assessed by Western blot analysis.

Figure 4 MEH63, MEH158 and MEH183 exhibited therapeutic efficacy in a mouse model of MRSA bacteraemia.

The bacterial colony-forming unit count in the blood of infected mice (n = 6), treated with MEH63, MEH158, MEH183, vancomycin, EB211 or normal saline BID for three days. The scFv combination was also administrated QD for three days.